Portfolio Company News

Lumena swings for a $75M IPO to bear down on liver diseases

Fierce Biotech
April 3, 2014
Damian Garde

A month removed from raising $45 million in venture backing, San Diego’s Lumena Pharmaceuticals wants $75 million more as it plots a Wall Street debut, piling up cash to advance its two liver treatments.  Read More

ZS Pharma Announces Start of Enrollment of Phase 3 Extended Dosing Study of ZS-9 in Patients with Hyperkalemia

Coppell, Texas – March 25, 2014 – ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia. (more…)

Lumena Pharmaceuticals Raises $45 Million in Series B Financing

Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis

SAN DIEGO – March 11, 2014 Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced that it has secured $45 million in Series B financing. (more…)

Companies To Watch: Otonomy Develops Proprietary Formulation For Ménière’s Disease

Pharmaceutical Online
March 3, 2014
By Wayne Koberstein, executive editor

Not to build a platform, but to create new, FDA -approved therapeutics for unserved indications in the ear, this developer focuses on novel delivery.

ZS Pharma Completes $55 Million Financing to Advance Its Novel Investigational Treatment for Hyperkalemia

Coppell, Texas – March 5, 2014 – ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular, and liver disorders, today announced that it has completed a $55 million Series D financing. (more…)

Tryton Medical Receives CE-mark for the Left Main Indication

Tryton Medical first & only coronary bifurcation stent indicated for Left Main

 Durham, N.C. – February 13, 2014Tryton Medical, Inc., the leading developer of stents designed to treat bifurcation lesions, announced that it has received CE Mark for the treatment of Left Main Coronary artery disease. (more…)

ZS Pharma Announces Positive Results from the Extended Treatment Phase of its Phase 3 Trial of ZS-9 in Patients with Hyperkalemia

Coppell, Texas –January 13, 2014ZS Pharma, a specialty pharmaceutical developing novel treatments for kidney, cardiovascular and liver disorders, today announced top-line results from the Extended Treatment Phase of ZS003, its pivotal Phase 3 trial of ZS-9. ZS-9 is a novel, investigational treatment for hyperkalemia. (more…)

Otonomy Doses First Subjects in Phase 3 Clinical Trials

Otonomy Doses First Subjects in Phase 3 Clinical Trials of OTO-201 in Pediatric Patients Undergoing Ear Tube Placement Surgery

Completion of study enrollment totaling roughly 500 subjects anticipated during Q2 2014

SAN DIEGO, December 11, 2013Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced dosing of the first patients in its two Phase 3 trials of OTO-201 (more…)

Otonomy Enrolls First Patient in Pivotal Phase 2b Study of OTO-104 in Ménière’s Disease

- FDA grants Fast Track designation for OTO-104 -

 SAN DIEGO, December 11, 2013Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced enrollment of the first patient in its pivotal Phase 2b study of OTO-104 for the reduction of vertigo in patients with unilateral Ménière’s disease. (more…)

Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases

Company receives first positive opinion in the European Union for Primary Sclerosing Cholangitis

 SAN DIEGO – November 18, 2013Lumena Pharmaceuticals Receives Positive Opinion for Orphan Drug Designation in the European Union for LUM001 in Four Rare Liver Diseases – Lumena Pharmaceuticals, a company developing oral therapeutics for rare liver diseases, today announced that it has received positive opinions for four Orphan Drug Designations by the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) for LUM001. (more…)

buy deer antler spray . Daddypromocodesnow . college paper writing service . where to buy garcinia cambogia australia